Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
Seeking Alpha10/29/2026Neutral
KYMR
Kymera Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$11.25B
P/E Ratio
—
EPS
$-3.64
Beta
2.03
52W High
$138.00
52W Low
$58.87
50-Day MA
$115.44
200-Day MA
$97.62
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Fundamentals
| Revenue (TTM) | $102.23M |
| Gross Profit (TTM) | $-327.75M |
| EBITDA | $-398.38M |
| Operating Margin | -396.00% |
| Return on Equity | -27.30% |
| Return on Assets | -17.60% |
| Revenue/Share (TTM) | $1.06 |
| Book Value | $18.92 |
| Price-to-Book | 6.79 |
| Price-to-Sales (TTM) | 110.00 |
| EV/Revenue | 98.45 |
| EV/EBITDA | -9.49 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 466.40% |
| Shares Outstanding | $85.37M |
| Float | $68.26M |
| % Insiders | 2.06% |
| % Institutions | 116.26% |
Historical Volatility
HV 10-Day
55.64%
HV 20-Day
51.54%
HV 30-Day
46.35%
HV 60-Day
43.27%
HV Rank
64.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($144.57 target)
4
Strong Buy17
Buy2
HoldLatest News
Kymera Therapeutics Q3 Earnings Call Highlights
Kymera Therapeutics NASDAQ: KYMR reported third-quarter results and outlined progress across its clinical pipeline, including phase I healthy-volunteer data for KT-579, an oral degrader targeting IRF5 for autoimmune diseases. The company also said it expects to report phase IIb data for its STAT6 degrader, KT-621, in atopic dermatitis by year-end.
MarketBeat10/29/2026Positive
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile
GlobeNewsWire10/29/2026Neutral
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-579 in healthy volunteers on Thursday, October 29, 2026, as part of its previously scheduled third quarter 2026 financial results. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.
GlobeNewsWire10/28/2026Neutral
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2026 financial results on October 29, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.
GlobeNewsWire10/22/2026Neutral
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.
Zacks Investment Research10/19/2026Neutral
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders. The investigation seeks to determine whether Kymera Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
PRNewsWire10/12/2026Neutral
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha9/15/2026Neutral
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/4/2026Positive
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
Zacks Investment Research9/3/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KYMR and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026